esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
Published 4 years ago • 2K plays • Length 3:11Download video MP4
Download video MP3
Similar videos
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
2:17
#esmo22 highlights on pembrolizumab with crt in locally advanced hnscc: the keynote-412 study
-
2:27
esmo 2020 highlights on neoadjuvant ici in early tnbc: the impassion031 study
-
2:21
prof. jean bourhis pembrolizumab versus cetuximab, concomitant with rt in la-hnscc: results
-
5:41
pembrolizumab vs cetuximab with radiotherapy in locally advanced hnscc
-
3:49
esmo highlights: genitourinary cancers
-
1:52
esmo 2022 highlights in head and neck cancer
-
35:16
highlights from esmo 2020
-
2:22
#esmo22 highlights on neoadj. vs adjuvant pembrolizumab in resected stage iii-iv melanoma:swog s1801
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
1:31
esmo oncologypro - intro by prof. a. matikas
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
3:04
esmo 2020 highlights on durability of clinical benefit and biomarkers with amg510 in nsclc
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
3:18
#esmo21 highlights on combination of pembrolizumab plus chemotherapy in mtnbc: the keynote-355 study
-
2:26
#esmo21 highlights on pembro chemo in 1st-line metastatic cervical cancer: the keynote-826 study